Daratumumab (anti-CD38)

目录号:A2027         批次号: A202702

打印

Daratumumab (anti-CD38) 是一种针对CD38的重组单克隆抗体。Daratumumab 是一种研究性的抗癌药物,适用于治疗多发性骨髓瘤的成年患者。MW =145.4 kDa。

抗体信息

CAS号 945721-28-8
配制 PBS Buffer, PH 7.4
推荐同型对照 Human IgG1
来源 Human
储存条件
(自收到货起)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
除菌 0.2 μM filtered
纯度 99%
蛋白浓度 5.72 mg/ml
内毒素 <1EU/mg

Daratumumab (anti-CD38)在文献中得到引用

In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology [ Leuk Res, 2024, 147:107599] PubMed: 39486120
Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro [ Brain Behav Immun Health, 2024, 42:100865] PubMed: 39411424
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma [ J Exp Med, 2022, 219(9)e20220214] PubMed: 35881112

禁止用于人体及治疗!